#Cumulus Neuroscience #NeuLogiq Platform #CNS Trials

Cumulus Neuroscience Reveals Transformative Insights at the ISCTM 2026 Autumn Conference

On September 16, 2026, Cumulus Neuroscience made a significant impact at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference held in Philadelphia, Pennsylvania. The company presented three compelling posters that highlighted groundbreaking data regarding patient engagement, adherence, and the usability of digital tools in clinical settings for a variety of Central Nervous System (CNS) disorders.

Overview of Cumulus Neuroscience's Efforts

These studies are pivotal, as traditional clinical trials related to CNS disorders often face challenges such as high costs, long durations, and participant burden. To address these issues, Cumulus has developed the NeuLogiq® Platform. This innovative platform was designed in collaboration with ten leading biopharma companies to gather objective, clinical-quality data through repeated digital measurements, both in clinical environments and at home.

The three posters presented aimed to answer crucial questions regarding patient interaction with frequent digital tracking and whether the data collected could inform trial design better than previous methodologies.

Study 1: Borderline Personality Disorder (BPD)

The first poster focused on usability and adherence in a remote study assessing Borderline Personality Disorder. Conducted in partnership with a top pharmaceutical company and a UK-based academic institution, the study involved 51 participants, 31 with BPD and 20 healthy control subjects. Patients utilized multiple digital measures, including cognitive assessments through the NeuLogiq Platform, mood ratings collected twice daily, and wrist-worn activity monitors.

Interim results indicated that 85% of the BPD group adhered to cognitive and EEG sessions, with mood assessment compliance reaching 90%. This high level of engagement and usability supports the notion that digital approaches may facilitate trials requiring less clinical contact while maintaining measurement frequency.

Study 2: Therapy-Resistant Depression

The second poster detailed a trial assessing neuroplasticity and cognition in patients undergoing treatment with esketamine for therapy-resistant depression. This study was conducted in collaboration with a leading pharmaceutical firm and an EU-based medical center. Initial findings showed that over 98% of in-clinic sessions and about 90% of at-home assessments were completed successfully, with minimal patient-reported burden related to these evaluations.

The researchers concluded that the NeuLogiq platform helps facilitate high-quality cognitive and neurophysiological assessments, demonstrating feasibility in real-world clinical contexts while allowing researchers to capture treatment effects on cognition more naturally.

Study 3: Alzheimer's Disease Screening

The final poster presented at the conference was an encore of research first shown at the Alzheimer's Association International Conference earlier in the year. This study evaluated a digital cognitive task called